EP0232410A1 - Procede et tampon de lyse pour l'extraction d'un antigene de surface de l'hepatite b a partir de cellules de levure - Google Patents

Procede et tampon de lyse pour l'extraction d'un antigene de surface de l'hepatite b a partir de cellules de levure

Info

Publication number
EP0232410A1
EP0232410A1 EP86905526A EP86905526A EP0232410A1 EP 0232410 A1 EP0232410 A1 EP 0232410A1 EP 86905526 A EP86905526 A EP 86905526A EP 86905526 A EP86905526 A EP 86905526A EP 0232410 A1 EP0232410 A1 EP 0232410A1
Authority
EP
European Patent Office
Prior art keywords
cells
hbsag
lysis buffer
hepatitis
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP86905526A
Other languages
German (de)
English (en)
Other versions
EP0232410A4 (fr
Inventor
Howard L. Levine
Mark Levine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of EP0232410A1 publication Critical patent/EP0232410A1/fr
Publication of EP0232410A4 publication Critical patent/EP0232410A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C12N1/063—Lysis of microorganisms of yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates in general to methods for extraction of Hepatitis B surface Antigen (HBsAg) and in particular to methods for extracting HBsAg which employ nonionic detergents.
  • HBsAg Hepatitis B surface Antigen
  • the hepatitis B virus causes a disease now known as hepatitis B, but formerly known as "serum hepatitis". It has been estimated that there are more . than 200,000,000 people who persistently have hepatitis B virus in their blood. Infection with the virus is a major cause of acute liver disease. Carriers of hepatitis B virus have a high risk of contracting cirrhosis and hepatocellular carcinoma.
  • the human hepatitis B virus has been identified with the "Dane" particle which is found in the serum of carriers and which is the causative agent of clinical hepatitis B infection.
  • the Dane particle is a 42 nanometer membrane structure which includes lipids, DNA, and at least four proteins: hepatitis B surface antigen (HBsAg), hepatitis B core antigen (HBcAg), hepatitis B e antigen (HBeAg), and a DNA polymerase.
  • HBsAg hepatitis B surface antigen
  • HBcAg hepatitis B core antigen
  • HBeAg hepatitis B e antigen
  • a DNA polymerase hepatitis B surface antigen
  • carriers also have 22 nanometer lipid particles which contain HBsAg but not DNA, HBcAg, HBeAg or DNA polymerase.
  • Hepatitis B vaccines currently in use employ 22 nanometer particles obtained from human plasma.
  • Human plasma used in the manufacture of hepatitis B vaccine has an antigen concentration of about 400 micrograms per milliliter. Because the total serum concentration is about 60 milligrams per liter, only a 150-fold purification is required.
  • plasma-derived hepatitis B vaccines are limited in supply and extreme caution must be exercised to insure that they are free 10 of all harmful contaminating material, including infectious viruses.
  • hepatitis B vaccine involves infecting cultured malignant cells, specifically hepatoma cells, with hepatitis B virus.
  • Monkey kidney cells transfected with - c recombinant plasmids containing the gene for HBsAg liberate HBsAg by lysis or by secretion.
  • Levinson, et al. European Patent Application No. 73,656.
  • production of hepatitis B vaccine from monkey kidney fibroblasts shares the drawbacks inherent in the production of hepatitis B vaccine from hepatoma cells.
  • the gene coding for HBsAg may be inserted into a bacterial plas id and may be amplified and expressed in several Escherichia coli host organisms.
  • Rutter, et al. European Patent Application No. 020,251.
  • this technique results in low yields because HBsAg is easily degraded within E. coli and the growth of E. coli is inhibited by HBsAg.
  • Miyanohara, et al. European Patent Application No. 105,049.
  • certain bacterial cell components for example lipopolysaccharides, are highly toxic to humans and pose purification problems.
  • bacteria being prokaryotes (i.e., members -of the group of organisms which lack in nucleus) may provide inefficient translation of the genes of eukaryotes (i.e., members of the group of organisms which possess a nucleus) inasmuch as: bacteria cannot perform certain processes, such as splicing out of introns or proteolytic clevage of precursor proteins; bacteria do not glycosylate, phosphorylate or methylate proteins, all of which are post-translational modifications which may be important for the immunogenicity of proteins; bacteria do not recognize the so-called signal peptide which is important for secretion of gene products in eukaryotes; and codon preference (i.e.
  • yeast offers several advantages for the production of eukaryotic gene products: yeast is readily grown in culture in large quantities; the technology of yeast culture on a large scale is well understood; because yeast cells are eukaryotic, they contain processing machinery for glycosylation, phosphorylation and methylation; and yeast cells better tolerate the HBsAg protein.
  • yeast-derived particles have an ED 5Q (a measure of the effective dose necessary to elicit an immune response) of 112 ng which is only slightly higher than the ED 5Q of 98 ng for mammalian cell-derived particles.
  • Burnette, et al. in "Modern Approaches to Vaccines", Chanock, et al., eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 245-250 (1984).
  • Protein micelles are aggregations of protein molecules having hydrophobic portions, which avoid contact with water molecules, and hydrophilic portions, which readily associate with water molecules. In a solution, the hydrophobic portions of the proteins in micelles become oriented toward the center of the micelle while the hydrophilic portions of the proteins are oriented toward the surface of the micelle.
  • Micelles formed from HBsAg protein molecules produce consistently higher levels of antibodies than are induced by intact Hepatitis B particles. Skelly, et al., Nature, 290, 51-54 (1981).
  • a micellar vaccine prepared from yeast HBsAg micelles has a slightly lower EDJ Q (22 ng) than micelles prepared from mammalian cells (25 ng). Burnette, et al., supra.
  • the process of extraction of polypeptides from the host cell is of importance for the preparation of polypeptide vaccines in general, and for the formation of micelles in particular.
  • Detergents may be employed for the extraction of membrane proteins. Different types of detergents have different effects upon the nature and activity of protein aggregates formed. Three detergents which may be employed for protein extraction are bile salts, ionic detergents and nonionic detergents.
  • Membrane proteins solubilized by bile salts may be precipitated out of salt solutions over a wide range of salt concentrations, a property useful for the separation of protein fractions. Tzagoloff et al., Methods in Enzymology, 22, 219-230 (1971). However, bile salts may dissociate integral membrane protein complexes so that native properties of an extracted protein, such as the state of aggregation, may not be maintained. Helenius et al.. Methods in Enzymology, 56, 734-749 (1979).
  • Ionic detergents are very effective solubilizing agents for membrane proteins. Tzagoloff et al., supra. However, ionic detergents nearly always denature proteins at the concentrations and temperatures required for complete solubilization of membranes. Helenius et al., supra.
  • Nonionic detergents are effective in dissociating lipids from proteins, but are relatively ineffective at disrupting protein-protein interactions. Helenius et al., supra. Thus, nonionic detergents are especially useful in preserving the structure of protein micelles during the extraction process.
  • Triton X-100 ® A nonionic detergent which may be employed to isolate viral membrane proteins is sold under the name Triton X-100 ® , a trademark of Rohm and Haas Co., Philadelphia, Pennsylvania.
  • Triton X-100 ® is an example of a group of commercially available, nonionic detergents having polar groups containing p ⁇ lyoxyethylene. Members of this group are almost always heterogenous in composition in that they contain a wide distribution of polyoxyethylene chain lengths. The chain length for a member of the group is commonly specified as an average chain length.
  • Triton X-100 ® may be -generically described as a polyethylene glycol p-isooctylphenyl ether having an average polyoxyethylene chain length of 9.6.
  • Helenius et al., supra contains lists of polyoxyethylene- containing detergents and information regarding their properties. Helenius et al, supra, is incorporated by reference herein.
  • Triton X-100 ® is used at various concentrations for the extraction of membrane proteins: at 0.05%, 0.3% and 2% for Semliki forest virus membrane proteins [Simons et al., J. Mol. Biol., 80,119-133 (1973); at 5% (v/v) for influenza virus envelope protein [Larin et al., J. Hy . Camb. , 69_, 35-46 (1971)]; at 2% with EDTA [Schnaitman, J. Bacteriol. ,108, 553-563 (1971)] or without EDTA [Schnaitman, J. Bacteriol., 108, 545-552 (1971)] for E. coli cytoplasmic membrane proteins and for E.
  • Methods for production of recombinant HBsAg polypeptides generally employ 0.1% or 2% concentrations of Triton X-100 ® as in Skelly et al, J. gen. Virol. , 44, 679 (1979) [Rutter et al, European Patent Application No. 62,574; Miyanohara et al., European Patent Application No. 105,149; Valenzuela et al, in "Modern Approaches to Vaccines," Chanock et al. eds., 209-213, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1984); and Valenzuela et al..
  • a nonionic detergent may be used to contact a chloroform-aqueous solution containing a viral suspension in order to obtain heavy subunits of influenza virus. Nevertheless, no suggestion is made that the use of a different concentration of nonionic detergent might result in a high yield of subcellular particles.
  • HBsAg may be isolated from serum as a mixture of particle types: small, spherical particles about 20 n in diameter; tubular particles about 20 nm in diameter; and large spherical particles about 42 nm in diameter with a core.
  • a method for conversion of these particle types into a uniform spherical particle of 18 to 22 nm in diameter involves heating affinity-puri ied HBsAg for from 5 to 120 minutes at 40 to 80 degrees C. (preferably 60 degrees C.) in an isotonic.
  • sodium chloride solution having' a pH ranging from 5 to 9 and prferably being 7.2; and containing 0.05% to 5% (preferably 0.5%) of a surfactant.
  • Surfactants useful according to this method include alkalai metal salts of bile acids, alkalai metal salts of lauroyl sarcosinic acid, polyoxyethylene alkyl phenols containing an average of 7-10 molecules of oxyethylene and polyoxyethylenesorbitan monoalkylester containing an average of 20 molecules of oxyethylene capable of delipidation in isotonic sodium chloride solution at about neutral pH.
  • HBsAg particles having a molecular weight of about 2,200,000 daltons are collected in an aqueous solution. The surfactant is removed from the aqueous solution of antigen particles by dialysis or gel filtration. Funakoshi, et al., U.S. Patent No. 4,113,712.
  • a yeast cell-lysis buffer according to the present invention enhances the recovery of subcellular particles.
  • the cell-lysis buffer includes an aqueous solution of a non-ionic detergent at a concentration within the range from about 0.5% to about 1.0% by volume.
  • a method according to the present invention provides for the highly efficient extraction of subcellular particles from cells.
  • the method involves suspending the cells in a lysis buffer comprising an aqueous solution of a non-ionic detergent at a concentration within the range from about 0.5% to about 1.0% by volume.
  • the method also involves maintaining the cells in the lysis buffer at a temperature within a range from about 3°C. to about 8°C.
  • the figure illustrates the effect of the concentration of Triton X-100 ® in a cell lysis buffer upon the recovery of HBsAg micellar particles from the lysis of yeast host cells.
  • Cells of S_ ⁇ cerevisiae expressing HBsAg according to Bitter, et al., Gene, 32, 263-274 (1984) 25 were suspended in approximately 2 volumes of lysis buffer to obtain a suspension having an ODg Q0 (optical density at 600 nm) of 10.
  • the operating chamber of the glass bead mill has a cooling jacket for controlling the temperature of the operating chamber containing the glass beads.
  • the amount of HBsAg particles released into solution were measured by a radioimmunoassay as available under the name AusriaTM Assay from Abbott Laboratories, North Chicago, Illinois.
  • the amount of protein was also measured by the Biuret method, as an indication of cell breakage.
  • Example I the buffer and method are utilized in a test tube scale model.
  • Example II the method and buffer are employed in a batch process.
  • Example III describes a preferred composition for the buffer and applies the buffer and method to a continuous process.
  • the concentration of Triton X-100 ® in the cell-lysis buffer described above was varied between 0% and 2% by volume and processed as described below.
  • HBsAg-expressing S ⁇ cerevisiae cells were suspended in 300 ml of a fermentation medium at O.D.10 (pH 4.45) and were centrifuged in a Beckman J6B centrifuge, available from Beckman Instruments, Mountain
  • the resulting pellet was resuspended in 30 ml of 10% glycerol, 50mM Tris, ImM EDTA, 150 mM NaCl, pH
  • Example II frozen cell pellets from HB ' sAg S_ ⁇ cerevisiae cell paste prepared according to Bitter, et al., supra, were prepared as indicated in Table II.
  • the cell pellet was resuspended in 4 volumes of 50 M Tris buffered containing lOmM EDTA, at pH 8.0 and at 4°C by using a mixer.
  • the resulting cell suspension was centrifuged in a Beckman J6B Centrifuge,as above, at 5000g (i.e. at 4000 rpm in a JS 4.2 rotor available from Beckman
  • Each pellet was resuspended in 1.5 volumes of 1% (v/v) Triton X-100 ® in the cell-lysis buffer as described above.
  • the cells were dispersed with a mixer and the pH of the solution was adjusted to 8.0 ⁇ 0.1 with 50% NaOH as needed.
  • recovery of 150% of the control values obtained in test tube runs may be obtained by the batchwise method of lysis.
  • EXAMPLE III HBsAg cell suspensions were prepared as in Example II with two of five samples of cells being suspended in 1% (v/v) Triton X-100 ® and three of five samples being suspended 0.5% (v/v) Triton X-100 ® .
  • a glass bead mill was primed by pumping 2 liters of cell-lysis buffer, described above,through the reaction chamber while chilling the mill 5° ⁇ 3°C. The mill was turned on and cold cell suspension was pumped into the mill. One retention volume of lysate was discarded while the remaining lysate was collected for further processing.
  • Run X-100 ® Wet Control Lysate (mg/Kg of % of No. (v/v%) Kg/ml) ⁇ g/OD-L) ( ⁇ g/OD-L) wet cells)
  • Control H- a Weight Control Lysate (mg/Kg of % of No. (v/v%) Kg/ml) ⁇ g/OD-L) ( ⁇ g/OD-L) wet cells)
  • the currently preferred buffer for cell-lysis is:

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un tampon de lyse de cellules de levure permettant de recueillir des particules subcellulaires comporte une solution aqueuse d'un détergent non ionique à une concentration se situant dans la plage comprise entre environ 0,5% et 1% en volume à une température comprise entre environ 3oC et environ 8oC. Le Triton X-100 R est un détergent non ionique préféré pour l'utilisation dans le tampon de lyse. Ce tampon de lyse peut être employé dans un procédé d'extraction de particules subcellulaires (par exemple des particules HBsAg) à partir de cellules (par exemple des cellules de levure génétiquement transformées) dont l'éclatement est provoqué en présence du tampon de lyse.
EP19860905526 1985-08-15 1986-08-15 Procede et tampon de lyse pour l'extraction d'un antigene de surface de l'hepatite b a partir de cellules de levure. Withdrawn EP0232410A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76604385A 1985-08-15 1985-08-15
US766043 1985-08-15

Publications (2)

Publication Number Publication Date
EP0232410A1 true EP0232410A1 (fr) 1987-08-19
EP0232410A4 EP0232410A4 (fr) 1988-01-25

Family

ID=25075224

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19860905526 Withdrawn EP0232410A4 (fr) 1985-08-15 1986-08-15 Procede et tampon de lyse pour l'extraction d'un antigene de surface de l'hepatite b a partir de cellules de levure.

Country Status (3)

Country Link
EP (1) EP0232410A4 (fr)
JP (1) JPS63501121A (fr)
WO (1) WO1987001128A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE903626A (fr) * 1985-11-13 1986-03-03 Labofina Sa Procede pour la recuperation de polypeptides localises dans l'espace periplasmique de la levure.
RU1389060C (ru) * 1986-08-13 1993-06-30 Институт иммунологии Способ получени рекомбинатной вакцины к гепатиту В
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
ATE91304T1 (de) * 1987-02-27 1993-07-15 Merck & Co Inc Verfahren zur herstellung des pres 1/s2/shepatitis-b-antigens aus hefe.
EP0314240A3 (fr) * 1987-10-26 1990-03-28 Merck & Co. Inc. Procédé de purification d'antigènes recombinants d'hépatite
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
CA1327851C (fr) * 1988-06-22 1994-03-15 Amy S. Christopher Imprimante reconfigurable
BE1009844A3 (fr) * 1995-12-22 1997-10-07 Genencor Int Procede de recolte d'une proteine.
KR100918098B1 (ko) * 2007-08-02 2009-09-24 대한민국 스트렙토마이세스 알부스 용균 추출물을 포함하는 백신 보좌제
CN105669826B (zh) * 2014-11-17 2021-02-26 苏州药明康德新药开发有限公司 酵母蛋白的提取试剂
JP6778867B2 (ja) * 2015-08-07 2020-11-04 国立大学法人山口大学 ポリペプチド抽出方法
CN111100795A (zh) * 2019-12-27 2020-05-05 深圳康泰生物制品股份有限公司 表达手足口病疫苗抗原的重组汉逊酵母细胞破碎缓冲液及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0075395A2 (fr) * 1981-09-02 1983-03-30 Biogen, Inc. Produits montrant l'antigénéité de l'antigène E du virus de l'hépatite B et méthode de production de ces antigènes
EP0110385A2 (fr) * 1982-11-30 1984-06-13 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Procédé de préparation de recombinants de poxvirus pour l'expression de gènes étrangers
EP0204680A2 (fr) * 1985-05-30 1986-12-10 Smithkline Biologicals S.A. Procédé d'isolement et de purification de l'antigène de surface de l'hépatite B

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847737A (en) * 1965-03-22 1974-11-12 A Kanarek Inactivation of myxoviruses and method of preparing a vaccine therefrom
US4113712A (en) * 1976-03-08 1978-09-12 The Green Cross Corporation HBsAG Particle composed of single polypeptide subunits and the preparation procedure
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
JPH0625069B2 (ja) * 1981-01-29 1994-04-06 ブリティッシュ・テクノロジー・グループ・リミテッド Ｂ型肝炎ワクチン製造方法
FR2549291B2 (fr) * 1982-10-29 1986-05-09 Radiotechnique Compelec Procede d'encapsulation de composants electroniques par extrusion de matiere plastique et applications a la fabrication de voyants lumineux et a l'encapsulation de circuits electroniques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0075395A2 (fr) * 1981-09-02 1983-03-30 Biogen, Inc. Produits montrant l'antigénéité de l'antigène E du virus de l'hépatite B et méthode de production de ces antigènes
EP0110385A2 (fr) * 1982-11-30 1984-06-13 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Procédé de préparation de recombinants de poxvirus pour l'expression de gènes étrangers
EP0204680A2 (fr) * 1985-05-30 1986-12-10 Smithkline Biologicals S.A. Procédé d'isolement et de purification de l'antigène de surface de l'hépatite B

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8701128A1 *

Also Published As

Publication number Publication date
JPS63501121A (ja) 1988-04-28
WO1987001128A1 (fr) 1987-02-26
EP0232410A4 (fr) 1988-01-25

Similar Documents

Publication Publication Date Title
Valenzuela et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast
Wingfield et al. Hepatitis core antigen produced in Escherichia coli: subunit composition, conformation analysis, and in vitro capsid assembly
Strauss Jr et al. Identification of the membrane protein and" core" protein of Sindbis virus.
US4977092A (en) Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US5314808A (en) Method for the transformation of cells, particularly eukaryotes by a DNA originating from viruses of hepatitis, more particularly from virus of a B viral hepatitis, and preparations containing the expression products of said DNAs
JPH0439445B2 (fr)
EP0232410A1 (fr) Procede et tampon de lyse pour l'extraction d'un antigene de surface de l'hepatite b a partir de cellules de levure
Heine et al. Entry of vesicular stomatitis virus into L cells
JPS61501897A (ja) 融合リポソ−ムおよびリポソ−ムの酸誘導融合方法
Olshevsky et al. Herpes simplex virus structural proteins
KR920007683B1 (ko) HBs항원의 정제방법
Hackett et al. The separation of infectious and autointerfering particles in vesicular stomatitis virus preparations
Bichko et al. Introduction of hepatitis delta virus into animal cell lines via cationic liposomes
JPH06172393A (ja) 宿主炭水化物含量が減少したＨＢｓＡｇエスケープ変異体ワクチン
Rolland et al. Purification of recombinant HBc antigen expressed in Escherichia coli and Pichia pastoris: comparison of size-exclusion chromatography and ultracentrifugation
Fraenkel-Conrat et al. Bacteriophages that contain lipid
JP2515432B2 (ja) 酵母から得られる組換え肝炎ｂ型ウイルス表面タンパク質を安定化する方法
Bancroft et al. The effect of an arginyl to a cysteinyl replacement on the uncoating behaviour of a spherical plant virus
McMaster et al. Rapid purification of covalently closed circular DNAs of bacterial plasmids and animal tumor viruses
JPH0734753B2 (ja) 組換え宿主細胞から得られる組換えｂ型肝炎ウイルス表面タンパク質の安定化方法
JP2637877B2 (ja) 宿主由来炭水化物成分を減少させたｂ型肝炎ウイルス表面タンパク質
CZ226993A3 (en) Set of surface proteins of particle-forming hepatitis b virus
EP0251460B1 (fr) Procédé de production d'antigène du noyau du virus de l'hépatite B (HBcAg) dans la levure
Yohn et al. Some physiochemical properties of Yaba poxvirus deoxyribonucleic acid
KR100257218B1 (ko) 비형간염바이러스표면항원단백질의제조방법및이를포함하는비형간염백신

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19870813

A4 Supplementary search report drawn up and despatched

Effective date: 19880125

17Q First examination report despatched

Effective date: 19900821

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMGEN INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920722

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEVINE, MARK

Inventor name: LEVINE, HOWARD, L.